Literature DB >> 11877336

The 5-series F(2)-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein.

Stéphanie Marlière1, Jean-Luc Cracowski, Thierry Durand, Olivier Chavanon, Janine Bessard, Alexandre Guy, Françoise Stanke-Labesque, Jean-Claude Rossi, Germain Bessard.   

Abstract

1. Among the F(2)-isoprostanes, the 15- and the 5-series are currently used as markers of lipid peroxidation in vascular diseases. 15-F(2t)-IsoP (also named iPF(2 alpha)-III) exerts a vasoconstriction in most vessels, whereas no data is available concerning 5-F(2t)-IsoP (also named iPF(2 alpha)-VI), which is more abundant in plasma. 2. The aim of this study was to determine whether 5-F(2t)-IsoP possess any vascular effects on various vessels including the isolated rat thoracic aorta, the human internal mammary artery and the saphenous vein. 3. In organ baths, 5-F(2t)-IsoP and its 5-epimer did not affect the basal tone of any vessel, unlike 15-F(2t)-IsoP. These compounds possessed no antagonist effects on 15-F(2t)-IsoP-induced contractions, No dilator effect was observed in comparison with sodium nitroprusside and acetylcholine on the rat aorta. 4. In conclusion, we show that unlike 15-F(2t)-IsoP, 5-F(2t)-IsoP and its 5-epimer possess no vasomotor effects and as such are unlikely to be involved in the pathogenesis of vascular diseases. Further studies are required to test whether these mediators may have effects on systems not being measured in the current study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877336      PMCID: PMC1573222          DOI: 10.1038/sj.bjp.0704558

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Characterization of the effects of isoprostanes on platelet aggregation in human whole blood.

Authors:  J H Cranshaw; T W Evans; J A Mitchell
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Increased formation of distinct F2 isoprostanes in hypercholesterolemia.

Authors:  M P Reilly; D Praticò; N Delanty; G DiMinno; E Tremoli; D Rader; S Kapoor; J Rokach; J Lawson; G A FitzGerald
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

3.  Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA.

Authors:  L Iuliano; D Praticò; C Greco; E Mangieri; G Scibilia; G A FitzGerald; F Violi
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

Review 4.  Vascular biology of the isoprostanes.

Authors:  J L Cracowski; P Devillier; T Durand; F Stanke-Labesque; G Bessard
Journal:  J Vasc Res       Date:  2001 Mar-Apr       Impact factor: 1.934

5.  Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine.

Authors:  H Li; J A Lawson; M Reilly; M Adiyaman; S W Hwang; J Rokach; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 6.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo.

Authors:  L J Roberts; J D Morrow
Journal:  Free Radic Biol Med       Date:  2000-02-15       Impact factor: 7.376

7.  8-Iso-PGF2 alpha induces beta 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury.

Authors:  L Fontana; C Giagulli; P Minuz; A Lechi; C Laudanna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-01       Impact factor: 8.311

8.  Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)].

Authors:  J L Cracowski; F Stanke-Labesque; P Devillier; O Chavanon; M Hunt; C Souvignet; G Bessard
Journal:  Eur J Pharmacol       Date:  2000-05-26       Impact factor: 4.432

9.  Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats.

Authors:  F Stanke-Labesque; P Devillier; S Veitl; F Caron; J L Cracowski; G Bessard
Journal:  Cardiovasc Res       Date:  2001-01       Impact factor: 10.787

10.  Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay.

Authors:  J Bessard; J L Cracowski; F Stanke-Labesque; G Bessard
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-25
View more
  6 in total

1.  The putative role of isoprostanes in human cardiovascular physiology and disease: following the fingerprints.

Authors:  J-L Cracowski
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

2.  Regulation of [³H]d-aspartate release by the 5-F(2t)-isoprostane and its 5-epimer in isolated bovine retina.

Authors:  Jamal Jamil; Ashley Wright; Na'cara Harrison; Edem Kegey; Arnecia Faye Flowers; Namonique Jarell Flyod; Casey Kotera; Alexandre Guy; Jean-Marie Galano; Thierry Durand; Ya Fatou Njie-Mbye; Sunny E Ohia; Catherine A Opere
Journal:  Neurochem Res       Date:  2011-11-13       Impact factor: 3.996

Review 3.  Isoprostane generation and function.

Authors:  Ginger L Milne; Huiyong Yin; Klarissa D Hardy; Sean S Davies; L Jackson Roberts
Journal:  Chem Rev       Date:  2011-08-18       Impact factor: 60.622

4.  15-F-isoprostane and 5-F-isoprostane are not triggers of myocardial preconditioning.

Authors:  Claire Arnaud; Jean-Luc Cracowski; Ahmed Hakim; Thierry Durand; Alexandre Guy; Diane Godin-Ribuot; Germain Bessard; Christophe Ribuot
Journal:  Clin Exp Pharmacol Physiol       Date:  2005 May-Jun       Impact factor: 2.557

5.  F(2)-isoprostanes as novel biomarkers for type 2 diabetes: a review.

Authors:  Subramanian Kaviarasan; Sekaran Muniandy; Rajes Qvist; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

6.  Oxidative stress in hypertensive patients induces an increased contractility in vein grafts independent of endothelial function.

Authors:  Claudio Joo Turoni; Rodrigo Marañón; Maria Karbiner; Juan Muntaner; Víctor Proto; María Peral de Bruno
Journal:  Int J Hypertens       Date:  2011-11-13       Impact factor: 2.420

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.